In a 14-to-6 vote, the FDA’s Oncologic Drugs Advisory Committee voted sufficient evidence has been provided to demonstrate the event-free survival benefit of eflornithine to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma.
Lexington, KY (PRWEB) October 05, 2021 CE Concepts, (“CEC” or the “Company”) an accredited provider of interprofessional continuing medical education and